Is AbbVie Inc. (ABBV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.6% / 30% | 1.3% / 30% | 3.1% / 30% | 0.43% / 5% | ✓ HALAL |
| DJIM | 16.6% / 33% | 1.3% / 33% | 3.1% / 33% | 0.43% / 5% | ✓ HALAL |
| MSCI | 50.4% / 33% | 3.9% / 33% | 9.4% / 33% | 0.43% / 5% | ✗ NOT HALAL |
| S&P | 16.6% / 33% | 1.3% / 33% | 3.1% / 33% | 0.43% / 5% | ✓ HALAL |
| FTSE | 50.4% / 33% | 3.9% / 33% | 9.4% / 50% | 0.43% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 71.6% | |
| Operating Margin | 34.1% | |
| Net Margin | 6.9% | |
| Return on Equity (ROE) | 6225.0% | |
| Return on Assets (ROA) | 9.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $19.0B |
| Free Cash Flow | $17.8B |
| Total Debt | $67.5B |
| Current Ratio | 0.7 |
| Total Assets | $134.0B |
Price & Trading
| Last Close | $211.12 |
| 50-Day MA | $221.74 |
| 200-Day MA | $215.72 |
| Avg Volume | 7.1M |
| Beta | 0.3 |
|
52-Week Range
$164.39
| |
About AbbVie Inc. (ABBV)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Purification Calculator
As a halal stock with 0.43% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AbbVie Inc. (ABBV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AbbVie Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AbbVie Inc.'s debt ratio?
AbbVie Inc.'s debt ratio is 16.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 50.4%.
Does AbbVie Inc. require dividend purification?
Yes, AbbVie Inc. has an impermissible income ratio of 0.43%, which means 0.43% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are AbbVie Inc.'s key financial metrics?
AbbVie Inc. has a market capitalization of $370.4B, trailing P/E ratio of 88.4, and revenue of $61.2B. The company maintains a gross margin of 71.6% and a net margin of 6.9%. Return on equity stands at 6225.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.